• Bowen Acquisition Corp (BOWN, Financial) received a NASDAQ delisting notice for not meeting key listing requirements.
• The company plans to appeal and pursue a merger with Shenzhen Qianzhi BioTechnology.
• Trading suspension is imminent without a successful appeal by July 22, 2025.
Bowen Acquisition Corp (BOWN, Financial), a special purpose acquisition company, has received a delisting determination letter from NASDAQ as of July 15, 2025. The delisting is due to non-compliance with several critical listing requirements, such as maintaining a $50 million minimum market value of listed securities, 1.1 million publicly held shares, a $15 million market value of publicly held shares, and having a minimum of 400 total shareholders.
BOWN has until July 22, 2025, to appeal this decision to a Nasdaq Hearings Panel. If no appeal is made, the trading of BOWN's securities will be suspended on July 24, 2025. Despite the immediate risk, the company intends to request a hearing and a stay of the trading suspension.
The company is actively trying to complete a previously announced business combination with Shenzhen Qianzhi BioTechnology Co. Ltd., which it believes will help regain compliance with NASDAQ’s listing requirements. However, there are no guarantees this merger will finalize or meet the necessary criteria. The current situation highlights significant compliance challenges for BOWN, leaving its trading status in a precarious position pending the outcome of its appeal and merger efforts.
